136 related articles for article (PubMed ID: 30648747)
1. Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2.
Dudenkov TM; Liu D; Cairns J; Devarajan S; Zhuang Y; Ingle JN; Buzdar AU; Robson ME; Kubo M; Batzler A; Barman P; Jenkins GD; Carlson EE; Goetz MP; Northfelt DW; Moreno-Aspitia A; Desta Z; Reid JM; Kalari KR; Wang L; Weinshilboum RM
Clin Pharmacol Ther; 2019 Jul; 106(1):219-227. PubMed ID: 30648747
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.
Cairns J; Ingle JN; Dudenkov TM; Kalari KR; Carlson EE; Na J; Buzdar AU; Robson ME; Ellis MJ; Goss PE; Shepherd LE; Goodnature B; Goetz MP; Weinshilboum RM; Li H; Bari MG; Wang L
JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32701512
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Gervasini G; Jara C; Olier C; Romero N; Martínez R; Carrillo JA
Br J Clin Pharmacol; 2017 Mar; 83(3):562-571. PubMed ID: 27747906
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Ingle JN; Schaid DJ; Goss PE; Liu M; Mushiroda T; Chapman JA; Kubo M; Jenkins GD; Batzler A; Shepherd L; Pater J; Wang L; Ellis MJ; Stearns V; Rohrer DC; Goetz MP; Pritchard KI; Flockhart DA; Nakamura Y; Weinshilboum RM
J Clin Oncol; 2010 Nov; 28(31):4674-82. PubMed ID: 20876420
[TBL] [Abstract][Full Text] [Related]
5. Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.
Hubalek M; Oberguggenberger A; Beer B; Meraner V; Sztankay M; Oberacher H; Schubert B; Wildt L; Seeber B; Giesinger J; Kemmler G; Holzner B; Sperner-Unterweger B
Clin Breast Cancer; 2014 Aug; 14(4):291-6. PubMed ID: 24468298
[TBL] [Abstract][Full Text] [Related]
6. TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression.
Liu M; Ingle JN; Fridley BL; Buzdar AU; Robson ME; Kubo M; Wang L; Batzler A; Jenkins GD; Pietrzak TL; Carlson EE; Goetz MP; Northfelt DW; Perez EA; Williard CV; Schaid DJ; Nakamura Y; Weinshilboum RM
Mol Endocrinol; 2013 Apr; 27(4):657-70. PubMed ID: 23518928
[TBL] [Abstract][Full Text] [Related]
7. SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.
Dudenkov TM; Ingle JN; Buzdar AU; Robson ME; Kubo M; Ibrahim-Zada I; Batzler A; Jenkins GD; Pietrzak TL; Carlson EE; Barman P; Goetz MP; Northfelt DW; Moreno-Aspita A; Williard CV; Kalari KR; Nakamura Y; Wang L; Weinshilboum RM
Breast Cancer Res Treat; 2017 Jul; 164(1):189-199. PubMed ID: 28429243
[TBL] [Abstract][Full Text] [Related]
8. Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics.
Liu M; Goss PE; Ingle JN; Kubo M; Furukawa Y; Batzler A; Jenkins GD; Carlson EE; Nakamura Y; Schaid DJ; Chapman JA; Shepherd LE; Ellis MJ; Khosla S; Wang L; Weinshilboum RM
Mol Endocrinol; 2014 Oct; 28(10):1740-51. PubMed ID: 25148458
[TBL] [Abstract][Full Text] [Related]
9. Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer.
Ingle JN; Kalari KR; Momozawa Y; Kubo M; Furukawa Y; Shepherd LE; Ellis MJ; Goss PE; Barman P; Carlson EE; Sinnwell JP; Tang X; Goetz MP; Chen BE; Cairns J; Weinshilboum RM; Wang L
Pharmacogenet Genomics; 2019 Oct; 29(8):183-191. PubMed ID: 31211741
[TBL] [Abstract][Full Text] [Related]
10. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Borrie AE; Rose FA; Choi YH; Perera FE; Read N; Sexton T; Lock M; Vandenberg TA; Hahn K; Younus J; Logan D; Potvin K; Yaremko B; Yu E; Lenehan J; Welch S; Teft WA; Kim RB
Breast Cancer Res Treat; 2020 Sep; 183(2):365-372. PubMed ID: 32632513
[TBL] [Abstract][Full Text] [Related]
11. Focus on anastrozole and breast cancer.
Mokbel K
Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
[TBL] [Abstract][Full Text] [Related]
12. The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.
Abubakar MB; Wei K; Gan SH
Pharmacogenet Genomics; 2014 Dec; 24(12):575-81. PubMed ID: 25203739
[TBL] [Abstract][Full Text] [Related]
13. Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer.
Ingle JN; Kalari KR; Barman P; Shepherd LE; Ellis MJ; Goss PE; Buzdar AU; Robson ME; Cairns J; Carlson EE; Eyman Casey A; Hoskin TL; Goodnature BA; Haddad TC; Goetz MP; Weinshilboum RM; Wang L
Pharmacogenet Genomics; 2021 Jan; 31(1):1-9. PubMed ID: 32649577
[TBL] [Abstract][Full Text] [Related]
14. Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors.
Streff A; Chu-Pilli M; Stopeck A; Chalasani P
Support Care Cancer; 2021 Jan; 29(1):187-191. PubMed ID: 32328775
[TBL] [Abstract][Full Text] [Related]
15. Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review.
Barros-Oliveira MDC; Costa-Silva DR; Andrade DB; Borges US; Tavares CB; Borges RS; Silva JM; Silva BBD
Rev Assoc Med Bras (1992); 2017 Apr; 63(4):371-378. PubMed ID: 28614542
[TBL] [Abstract][Full Text] [Related]
16. Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.
Ingle JN; Xie F; Ellis MJ; Goss PE; Shepherd LE; Chapman JW; Chen BE; Kubo M; Furukawa Y; Momozawa Y; Stearns V; Pritchard KI; Barman P; Carlson EE; Goetz MP; Weinshilboum RM; Kalari KR; Wang L
Cancer Res; 2016 Dec; 76(23):7012-7023. PubMed ID: 27758888
[TBL] [Abstract][Full Text] [Related]
17. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I; Itoh T; Chen S
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
[TBL] [Abstract][Full Text] [Related]
18. Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?
Oberguggenberger A; Meraner V; Sztankay M; Beer B; Weigel G; Oberacher H; Kemmler G; Czech T; Holzner B; Wildt L; Sperner-Unterweger B; Daniaux M; Hubalek M
BMC Cancer; 2017 Mar; 17(1):226. PubMed ID: 28351392
[TBL] [Abstract][Full Text] [Related]
19. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.
Boccardo F; Rubagotti A; Guglielmini P; Fini A; Paladini G; Mesiti M; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
Ann Oncol; 2006 Jun; 17 Suppl 7():vii10-4. PubMed ID: 16760270
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]